Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab

Retina

Volumn 29, Issue 5, 2009, Pages 579-585

  Nonobe, Norie Ito ^a   Kachi, Shu ^a   Kondo, Mineo ^a   Takai, Yoshiko ^a   Takemoto, Koji ^a   Nakayama, Atsushi ^a   Hayakawa, Masahiro ^a   Terasaki, Hiroko ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; AQUEOUS HUMOR; ARTICLE; BIOMICROSCOPY; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL CATARACT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INFANT; INFORMED CONSENT; JAPAN; LENSECTOMY; MALE; OPHTHALMOSCOPY; PARENT; PROTEIN BINDING; RETROLENTAL FIBROPLASIA; UNIVERSITY HOSPITAL; VITRECTOMY; CLASSIFICATION; DRUG ANTAGONISM; GESTATIONAL AGE; INJECTION; METABOLISM; NEWBORN; TREATMENT OUTCOME; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS; RETINOPATHY OF PREMATURITY; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; VITREOUS BODY;

EID: 66349135966     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181a3b848     Document Type: Article

References (16)

1. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
2. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
3. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118: 445-450.
4. Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15(7 Pt 1):4738-4747.
5. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10. Review.
6. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053.
7. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
8. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-e15.
9. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700.
10. Sawada O, Kawamura H, Kakinoki M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol 2007;125:1363-1366.
11. Hiraoka M, Watanabe T, Kawakami T, et al. Retinopathy of prematurity in extremely low birth weight infants: a Tokyo multicenter study. Nippon Ganka Gakkai Zasshi 2004;108: 600-605.
12. Chung EJ, Kim JH, Ahn HS, et al. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2007;245:1727-1730.
13. Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000;156:1337-1344.
14. Sonmez K, Drenser KA, Caoine A Jr. et al. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115:1065-1070.e1.
15. ICROP Committee for Classification of Late stages ROP. An international classification of retinopathy of prematurity, II: the classification of retinal detachment. Arch Ophthalmol 1987;105:906-912.
16. Funatsu H, Yamashita H, Noma H, et al. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Eye 2007;21:377-382.